NEW YORK (GenomeWeb News) – The Danish drug discovery firm Nuevolution said today that it will collaborate with Cancer Research Technology, the commercial branch of Cancer Research UK, to identify possible drug candidates for use in cancer treatments.

Under the collaboration, Nuevolution will use its Chemetics technology, which uses DNA labeling for small-molecule drug screening, to identify drug leads that block the activity of a number of cancer targets, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.